



SAFETY DATA SHEET

Revision date 04-Aug-2023

Version 2

Page 1 / 13

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name Gemcitabine (gemcitabine hydrochloride) for Injection (Hospira, Inc.)
Product Code(s) PZ03241
Synonyms Gemcitabine for Injection, USP (Lyophilized)
Trade Name: Not applicable
Chemical Family: Mixture

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product used as Antineoplastic

1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira UK Limited
Horizon
Honey Lane
Hurley
Maidenhead, SL6 6RJ
United Kingdom

E-mail address pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

GHS - Classification: Regulated according to Regulation (EC) 1272/2008 and/or other applicable regulations.

Acute toxicity - Oral	Category 4 - (H302)
Skin corrosion/irritation	Category 2 - (H315)
Serious eye damage/eye irritation	Category 2A - (H319)
Germ cell mutagenicity	Category 1B - (H340)
Reproductive toxicity	Category 1B - (H360FD)

OSHA Classification
Physical Hazard Combustible Dust

2.2. Label elements

Signal word Danger

Hazard statements
H302 - Harmful if swallowed
H315 - Causes skin irritation
H319 - Causes serious eye irritation
H360FD - May damage fertility. May damage the unborn child
H340 - May cause genetic defects

SAFETY DATA SHEET

Product Name Gemcitabine (gemcitabine hydrochloride) for Injection
(Hospira, Inc.)
Revision date 04-Aug-2023

Page 2 / 13

Version 2

OSHA - May form combustible dust concentrations in air

Precautionary Statements

P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P270 - Do not eat, drink or smoke when using this product
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P264 - Wash hands thoroughly after handling
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P302+ P352 - IF ON SKIN: Wash with plenty of soap and water
P332 + P313 - If skin irritation occurs: Get medical advice/attention
P362 + P364 - Take off contaminated clothing and wash it before reuse
P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing
P337 + P313 - If eye irritation persists: Get medical advice/attention
P301 + P312 - IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell
P330 - Rinse mouth
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations



2.3. Other hazards

Other hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances

Not applicable

3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Gemcitabine hydrochloride (CAS #: 122111-03-9)	45-55		Not Listed	Acute Tox. 4 (H302) Eye Irrit. 2B (H319) Skin Irrit. 2 (H315)	Not Listed	No data available	No data available

SAFETY DATA SHEET

Product Name Gemcitabine (gemcitabine hydrochloride) for Injection
(Hospira, Inc.)
Revision date 04-Aug-2023

Page 3 / 13

Version 2

				Repr. 1B (H360FD) Muta. 1B (H340)			
Sodium hydroxide (CAS #: 1310-73-2)	**	-	215-185-5	Skin Corr. 1A (H314)	Eye Irrit. 2 :: 0.5%<=C<2% Skin Corr. 1A :: C>=5% Skin Corr. 1B :: 2%<=C<5% Skin Irrit. 2 :: 0.5%<=C<2%	No data available	No data available
+ Hydrochloric Acid (CAS #: 7647-01-0)	**	-	231-595-7	Acute Tox. 3 (H331) Skin Corr. 1A (H314) Press. Gas	Eye Irrit. 2 :: 10%<=C<25% Skin Corr. 1B :: C>=25% Skin Irrit. 2 :: 10%<=C<25% STOT SE 3 :: C>=10%	No data available	No data available

NonHazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Sodium acetate trihydrate (CAS #: 6131-90-4)	*		Not Listed	Not classified as hazardous	Not Listed	No data available	No data available
Mannitol (CAS #: 69-65-8)	*	-	200-711-8	Not classified as hazardous	Not Listed	No data available	No data available

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate

No information available

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Gemcitabine hydrochloride 122111-03-9	>500	No data available	No data available	No data available	No data available
Sodium hydroxide 1310-73-2	325	1350	No data available	No data available	No data available
Mannitol 69-65-8	13500	No data available	No data available	No data available	No data available
+ Hydrochloric Acid 7647-01-0	238	5010	No data available	No data available	563.3022

Additional information

* Proprietary

** to adjust pH

+ Substance with a Union workplace exposure limit

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret. Non-hazardous ingredients provided for

SAFETY DATA SHEET

Product Name Gemcitabine (gemcitabine hydrochloride) for Injection
(Hospira, Inc.)
Revision date 04-Aug-2023

Page 4 / 13

Version 2

completeness.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation	Remove to fresh air. Seek immediate medical attention/advice.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
Skin contact	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
--	--

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians	None.
---------------------------	-------

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media	Dry chemical, CO2, alcohol-resistant foam or water spray.
-------------------------------------	---

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical	Fine particles (such as dust and mists) may fuel fires/explosions.
Hazardous combustion products	Formation of toxic gases is possible during heating or fire.

5.3. Advice for firefighters

Special protective equipment for fire-fighters	Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.
---	--

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions	Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
For emergency responders	Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.
----------------------------------	--

6.3. Methods and material for containment and cleaning up

SAFETY DATA SHEET

Product Name Gemcitabine (gemcitabine hydrochloride) for Injection
(Hospira, Inc.)
Revision date 04-Aug-2023

Page 5 / 13

Version 2

Methods for containment
Methods for cleaning up
Prevention of secondary hazards

Prevent further leakage or spillage if safe to do so.
Avoid use of a filtered vacuum to clean spills of dry solids. Contain the source of the spill or leak. Clean spill area thoroughly. Collect spilled material by a method that controls dust generation.
Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling

Restrict access to work area. Minimize dust generation and accumulation. Avoid breathing dust. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s) Pharmaceutical drug product. Antineoplastic.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Gemcitabine hydrochloride

Pfizer OEL TWA-8 Hr: 0.05 µg/m³

Sodium hydroxide

ACGIH OEL (Ceiling)	2 mg/m ³
ACGIH TLV	Ceiling: 2 mg/m ³
Austria	2 mg/m ³
	STEL 4 mg/m ³
Bulgaria	2.0 mg/m ³
Czech Republic	1 mg/m ³
	Ceiling: 2 mg/m ³
Denmark	Ceiling: 2 mg/m ³
Estonia	1 mg/m ³
	STEL: 2 mg/m ³
Finland	Ceiling: 2 mg/m ³
France	2 mg/m ³
Hungary	1 mg/m ³
	STEL: 2 mg/m ³
Ireland	STEL: 2 mg/m ³
Ceiling Limit Value	2 mg/m ³
Latvia	0.5 mg/m ³
Poland	STEL: 1 mg/m ³

SAFETY DATA SHEET

Product Name Gemcitabine (gemcitabine hydrochloride) for Injection
(Hospira, Inc.)
Revision date 04-Aug-2023

Page 6 / 13

Version 2

Romania	0.5 mg/m ³ 1 mg/m ³ STEL: 3 mg/m ³
Slovakia	2 mg/m ³
Spain	STEL: 2 mg/m ³
Switzerland	2 mg/m ³ STEL: 2 mg/m ³
OSHA PEL	2 mg/m ³ (vacated) Ceiling: 2 mg/m ³ STEL: 2 mg/m ³
United Kingdom	
Mannitol	
Russia	MAC: 10 mg/m ³
+ Hydrochloric Acid	
ACGIH OEL (Ceiling)	2 ppm
ACGIH TLV	Ceiling: 2 ppm
Austria	5 ppm 8 mg/m ³ STEL 10 ppm
Bulgaria	STEL 15 mg/m ³ STEL: 10 ppm STEL: 15.0 mg/m ³ 5 ppm 8.0 mg/m ³
Czech Republic	8 mg/m ³ Ceiling: 15 mg/m ³
Estonia	5 ppm 8 mg/m ³ STEL: 10 ppm STEL: 15 mg/m ³
European Union	TWA: 5 ppm TWA: 8 mg/m ³ STEL: 10 ppm STEL: 15 mg/m ³
Finland	STEL: 5 ppm STEL: 7.6 mg/m ³
Germany	2 ppm 3.0 mg/m ³ Ceiling / Peak: 4 ppm Ceiling / Peak: 6 mg/m ³
Germany	2 ppm 3 mg/m ³
Hungary	8 mg/m ³ STEL: 16 mg/m ³
Ireland	8 mg/m ³ 5 ppm STEL: 10 ppm STEL: 15 mg/m ³
Italy	5 ppm 8 mg/m ³ STEL: 10 ppm STEL: 15 mg/m ³
Ceiling Limit Value	2 ppm 3.0 mg/m ³
Latvia	5 ppm 8 mg/m ³ STEL: 10 ppm STEL: 15 mg/m ³
Netherlands	8 mg/m ³ STEL: 15 mg/m ³

SAFETY DATA SHEET

Product Name Gemcitabine (gemcitabine hydrochloride) for Injection
(Hospira, Inc.)
Revision date 04-Aug-2023

Page 7 / 13

Version 2

Poland	STEL: 10 mg/m ³ 5 mg/m ³
Romania	5 ppm 8 mg/m ³ STEL: 10 ppm STEL: 15 mg/m ³
Russia	MAC: 5 mg/m ³
Slovakia	5 ppm 8.0 mg/m ³
Spain	5 ppm 7.6 mg/m ³ STEL: 10 ppm STEL: 15 mg/m ³
Switzerland	2 ppm 3 mg/m ³ STEL: 4 ppm STEL: 6 mg/m ³
U.S. - OSHA - Final PELs - Ceiling Limits	5 ppm 7 mg/m ³
OSHA PEL	(vacated) Ceiling: 5 ppm (vacated) Ceiling: 7 mg/m ³ Ceiling: 5 ppm Ceiling: 7 mg/m ³
United Kingdom	TWA: 1 ppm TWA: 2 mg/m ³ STEL: 5 ppm STEL: 8 mg/m ³

8.2. Exposure controls

Engineering controls

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section. It is recommended that all operations be fully enclosed and no air recirculated.

Environmental exposure controls

No information available.

Personal protective equipment

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Eye/face protection

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

Hand protection

Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

Skin and body protection

Impervious disposable protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

Respiratory protection

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.).

SAFETY DATA SHEET

Product Name Gemcitabine (gemcitabine hydrochloride) for Injection
(Hospira, Inc.)
Revision date 04-Aug-2023

Page 8 / 13

Version 2

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical state	Lyophilized powder
Color	White to off-white
Odor	No information available.
Odor threshold	No information available
Molecular formula	Mixture
Molecular weight	Mixture

Property

pH	<u>Values</u> No data available
Melting point / freezing point	No data available
Boiling point / boiling range	
Flash point	No information available
Evaporation rate	No data available
Flammability (solid, gas)	No data available
Flammability Limit in Air	
Upper flammability limit:	No data available
Lower flammability limit:	No data available

Vapor pressure	No data available
Vapor density	No data available
Relative density	No data available
Water solubility	No data available
Solubility(ies)	No data available
Partition coefficient	No data available
Autoignition temperature	No data available
Decomposition temperature	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available
Explosive properties	No information available

9.2. Other information

No information available

9.2.1. Information with regard to physical hazard classes

No information available

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity No data available.

10.2. Chemical stability

SAFETY DATA SHEET

Product Name Gemcitabine (gemcitabine hydrochloride) for Injection
(Hospira, Inc.)
Revision date 04-Aug-2023

Page 9 / 13

Version 2

Stability Stable under normal conditions.

Explosion data

Sensitivity to Mechanical Impact No data available.

Sensitivity to Static Discharge No data available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

Conditions to avoid Fine particles (such as dust and mists) may fuel fires/explosions.

10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information: The information included in this section describes the potential hazards of the individual ingredients

Short term May be absorbed through the skin and cause systemic effects.

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on reproductive system and blood and blood forming organs Animal studies have shown a potential to cause adverse effects on the fetus.

Known Clinical Effects: Adverse effects associated with therapeutic use include decreased blood cell count, nausea, vomiting, swelling, skin rash, liver enzyme changes, flu-like syndrome.

Acute toxicity Classification is based on mixture calculation methods based on component data

Serious eye damage/eye irritation Classification is based on mixture calculation methods based on component data.

Skin corrosion/irritation Classification is based on mixture calculation methods based on component data.

Respiratory or skin sensitization Based on available data, the classification criteria are not met.

STOT - single exposure Based on available data, the classification criteria are not met.

STOT - repeated exposure Based on available data, the classification criteria are not met.

Reproductive toxicity Classification is based on mixture calculation methods based on component data.

Germ cell mutagenicity Classification is based on mixture calculation methods based on component data.

Carcinogenicity Based on available data, the classification criteria are not met.

Aspiration hazard Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose)

Gemcitabine hydrochloride

Mouse Oral Minimum Lethal Dose 333 mg/kg

Rat Oral LD50 > 500 mg/kg

Rabbit Dermal LD50 > 1000 mg/kg

Mannitol

Rat Oral LD 50 13500 mg/kg

Mouse Oral LD 50 22 g/kg

Sodium hydroxide

Mouse IP LD50 40 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Sodium hydroxide	= 325 mg/kg (Rat)	= 1350 mg/kg (Rabbit)	-
Mannitol	= 13500 mg/kg (Rat)	-	-
+ Hydrochloric Acid	238 - 277 mg/kg (Rat)	> 5010 mg/kg (Rabbit)	= 1.68 mg/L (Rat) 1 h

SAFETY DATA SHEET

Product Name Gemcitabine (gemcitabine hydrochloride) for Injection
(Hospira, Inc.)
Revision date 04-Aug-2023

Page 10 / 13

Version 2

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Gemcitabine hydrochloride

Skin irritation Rabbit Irritant

Eye irritation Rabbit Irritant

+ Hydrochloric Acid

Skin irritation Severe

Eye irritation Severe

Sodium hydroxide

Eye Irritation Rabbit Severe

Skin Irritation Rabbit Severe

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Gemcitabine hydrochloride

6 Month(s) Dog No route specified 0.04 mg/kg/day NOAEL Blood, Erythroid cells, Lymphoid tissue, Immune system

6 Month(s) Mouse No route specified 0.006 mg/kg/day LOAEL Erythroid cells, Male reproductive system, Spleen

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Gemcitabine hydrochloride

Reproductive & Fertility Mouse Intraperitoneal 0.05 mg/kg/day NOAEL Fertility

Fertility and Embryonic Development Mouse Intravenous 0.25 mg/kg/day LOAEL Fetotoxicity, Embryotoxicity, Maternal Toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Gemcitabine hydrochloride

In Vivo Micronucleus Mouse Positive

In Vitro Mammalian Cell Mutagenicity Mouse Lymphoma Positive

Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative

In Vivo Sister Chromatid Exchange Negative

In Vitro Chromosome Aberration Negative

+ Hydrochloric Acid

Bacterial Mutagenicity (Ames) *Salmonella* Negative

In Vivo Micronucleus Rat Negative

Carcinogenicity None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

+ Hydrochloric Acid

IARC

Group 3 (Not Classifiable)

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties No information available.

11.2.2. Other information

Other adverse effects No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

12.1. Toxicity

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

SAFETY DATA SHEET

Product Name Gemcitabine (gemcitabine hydrochloride) for Injection
(Hospira, Inc.)
Revision date 04-Aug-2023

Page 11 / 13

Version 2

Gemcitabine hydrochloride

Oncorhynchus mykiss (Rainbow Trout) LC50 96 hours > 1043 mg/L

Pimephales promelas (Fathead Minnow) LC50 96 > 1014 mg/L

Daphnia Magna (Water Flea) EC50 48 hours > 999 mg/L

Selenastrum capricornutum (Green Alga) EC50 5.4 mg/L

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

Gemcitabine hydrochloride

Nostoc sp. (Freshwater Cyanobacteria) MIC 800 mg/L

Aspergillus niger (Fungus) MIC > 1000 mg/L

12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

Bioaccumulation No information available.

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment

Chemical name	PBT and vPvB assessment
Sodium hydroxide	The substance is not PBT / vPvB PBT assessment does not apply
+ Hydrochloric Acid	The substance is not PBT / vPvB PBT assessment does not apply

12.6. Endocrine disrupting properties

Endocrine disrupting properties No information available.

12.7. Other adverse effects

No information available.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

SAFETY DATA SHEET

Product Name Gemcitabine (gemcitabine hydrochloride) for Injection
(Hospira, Inc.)
Revision date 04-Aug-2023

Page 12 / 13

Version 2

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

UN number: Not applicable
UN proper shipping name: Not applicable
Transport hazard class(es): Not applicable
Packing group: Not applicable
Environmental Hazard(s): Not applicable

Special precautions for user: Not applicable

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Gemcitabine hydrochloride	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed
Sodium acetate trihydrate	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed
AICS	Present
Sodium hydroxide	
CERCLA/SARA Section 313 de minimus %	Not Listed
Hazardous Substances RQs	1000 lb
California Proposition 65	Not Listed
TSCA	Present
EINECS	215-185-5
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 5 Schedule 6
Mannitol	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	200-711-8
AICS	Present
+ Hydrochloric Acid	
CERCLA/SARA Section 313 de minimus %	1.0 %
Hazardous Substances RQs	5000 lb
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-595-7
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 5 Schedule 6

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This

SAFETY DATA SHEET

Product Name Gemcitabine (gemcitabine hydrochloride) for Injection
(Hospira, Inc.)
Revision date 04-Aug-2023

Page 13 / 13

Version 2

product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH Annex XVII	Substance subject to authorization per REACH Annex XIV
Sodium hydroxide - 1310-73-2	Use restricted. See item 75.	
+ Hydrochloric Acid - 7647-01-0	Use restricted. See item 75.	

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

Chemical name	Lower-tier requirements (tons)	Upper-tier requirements (tons)
+ Hydrochloric Acid - 7647-01-0	25	250

Chemical name	EU - Biocides
+ Hydrochloric Acid - 7647-01-0	Product-type 2: Disinfectants and algacides not intended for direct application to humans or animals

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

AICS - Australian Inventory of Chemical Substances

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of H-Statements referred to under section 3

Acute toxicity, oral-Cat.4; Skin corrosion/irritation-Cat.2; H315 - Causes skin irritation Germ cell mutagenicity-Cat.1B; H340 - May cause genetic defects Reproductive toxicity-Cat.1B; H360FD - May damage fertility. May damage the unborn child Serious eye damage/eye irritation-Cat. 2; H319 - Causes serious eye irritation Skin corrosion/irritation-Cat.1A; H314 - Causes severe skin burns and eye damage Acute toxicity, inhalation-Cat.3; H331 - Toxic if inhaled

Data Sources: Publicly available toxicity information. Safety data sheets for individual ingredients.

Reason for revision Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 8 - Exposure Controls / Personal Protection. Added Pfizer OEL (Section 8). Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information.

Revision date 04-Aug-2023

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.